Press Releases

Date Title and Summary Additional Formats
Toggle Summary Option-based Collaboration to Develop Two CAR T-Cell Product Candidates Using Fate’s Proprietary iPSC Product Platform SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed Read All » View HTML
Toggle Summary New Approach Uses CRISPR-mediated Genome Activation for iPSC Generation SAN DIEGO , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune Read All » View HTML
Toggle Summary SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All » View HTML
Toggle Summary SAN DIEGO , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All » View HTML
Toggle Summary Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell Product FT500 Licensed Novel CAR Constructs from Memorial Sloan Kettering Cancer Center for Off-the-Shelf Read All » View HTML
Toggle Summary SAN DIEGO , July 30, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML
Toggle Summary SAN DIEGO , June 01, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All » View HTML
Toggle Summary Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CAR T-cell Collaboration at ASGCT 2018 SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular Read All » View HTML
Toggle Summary No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 Submission Read All » View HTML
Toggle Summary SAN DIEGO , May 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.